波兰重症COVID-19相关急性呼吸窘迫综合征的体外膜氧合治疗:一项多中心队列研究
该回顾性多中心队列研究分析了2020年3月1日至2021年5月31日期间波兰参与中心收治的158例因COVID-19难治性低氧血症接受ECMO的患者,其中77.8%由其他机构转入,31%在ECMO支持状态下转运。ECMO平均治疗时长18.0±13.5天,ICU粗死亡率为74.1%。多因素分析显示,院内死亡与ECMO前乳酸水平(每1 mmol/L,OR 2.10,p=0.017)和BMI(每5 kg/m2,OR 1.47,p=0.050)独立相关。
要点
- 158例因COVID-19接受ECMO的患者中,ICU粗死亡率为74.1%,41例存活者中37例成功脱离ECMO、4例成功接受肺移植。
- ECMO前乳酸水平每升高1 mmol/L,院内死亡风险OR为2.10(p=0.017),为独立相关因素。
- BMI每增加5 kg/m2,院内死亡风险OR为1.47(p=0.050),为独立相关因素。
- 77.8%的患者由其他机构转入ECMO中心,31%在体外生命支持状态下转运;ECMO平均治疗时长18.0±13.5天。
适用人群与场景
- 2020年3月1日至2021年5月31日期间,波兰参与中心收治的因COVID-19难治性低氧血症需要ECMO的成人患者,共158例纳入分析(另有13例在观察期结束时仍在接受ECMO)。
- 患者平均年龄46.3±9.8岁,88%在2020年10月1日之后接受治疗,77.8%由其他机构转入ECMO中心,31%在体外生命支持状态下转运。
研究设计与关键结果
- 研究类型:回顾性多中心队列研究,时间跨度为2020年3月1日至2021年5月31日(15个月)。
- 共171例患者入住参与中心并因COVID-19难治性低氧血症需要ECMO,其中158例纳入分析,13例在观察期结束时仍需要ECMO。
- ECMO平均治疗时长为18.0±13.5天;ICU粗死亡率为74.1%。
- 41例存活者中,37例成功脱离ECMO支持,4例成功接受肺移植。
- 多因素分析显示,院内死亡与ECMO前乳酸水平独立相关(每1 mmol/L,OR 2.10,p=0.017),与BMI独立相关(每5 kg/m2,OR 1.47,p=0.050)。
证据类型、等级与局限
- 证据类型:回顾性多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于因COVID-19难治性低氧血症考虑ECMO的患者,ECMO前乳酸水平升高和BMI较高与院内死亡风险独立相关,OR分别为每1 mmol/L 2.10(p=0.017)和每5 kg/m2 1.47(p=0.050)。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In Poland, the clinical characteristics and outcomes of patients with COVID-19 requiring extracorporeal membrane oxygenation (ECMO) remain unknown. This study aimed to answer these unknowns by analyzing data collected from high-volume ECMO centers willing to participate in this project.
METHODS: This retrospective, multicenter cohort study was completed between March 1, 2020, and May 31, 2021 (15 months). Data from all patients treated with ECMO for COVID-19 were analyzed. Pre-ECMO laboratory and treatment data were compared between non-survivors and survivors. Independent predictors for death in the intensive care unit (ICU) were identified.
RESULTS: There were 171 patients admitted to participating centers requiring ECMO for refractory hypoxemia due to COVID-19 during the defined time period. A total of 158 patients (mean age: 46.3 ± 9.8 years) were analyzed, and 13 patients were still requiring ECMO at the end of the observation period. Most patients (88%) were treated after October 1, 2020, 77.8% were transferred to ECMO centers from another facility, and 31% were transferred on extracorporeal life support. The mean duration of ECMO therapy was 18.0 ± 13.5 days. The crude ICU mortality rate was 74.1%. In the group of 41 survivors, 37 patients were successfully weaned from ECMO support and four patients underwent a successful lung transplant. In-hospital death was independently associated with pre-ECMO lactate level (OR 2.10 per 1 mmol/L, p = 0.017) and BMI (OR 1.47 per 5 kg/m2, p = 0.050).
CONCLUSIONS: The ICU mortality rate among patients requiring ECMO for COVID-19 in Poland was high. In-hospital death was independently associated with increased pre-ECMO lactate levels and BMI.
参考来源
- Trejnowska E, Drobiński D, Knapik P, et al. Extracorporeal membrane oxygenation for severe COVID-19-associated acute respiratory distress syndrome in Poland: a multicenter cohort study. Crit Care. 2022. PMID: 35392960. doi:10.1186/s13054-022-03959-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。